Markers for Early Detection of Cardiac Diseases

References

• Granger C. B., Van eyk J. E., Mockrin S. C., Anderson A. N. National Heart, Lung, and Blood Institute Clinical Proteomics Working Group Report. Circulation 2004; 109: 1697–703
   PubMedGoogle Scholar
• Liuzzo G., Biasucci L. M., Gallimore J. R. The prognostic value of C‐reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417–424
   PubMed Web of Science ®Google Scholar
• Ridker P. M. High‐sensitivity C‐reactive protein (hs‐CRP): a potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813–8
   PubMed Web of Science ®Google Scholar
• Biasucci L. M., Abbate A., Liuzzo G. Prognostic role of plasma high‐sensitivity C‐reactive protein levels in acute coronary syndromes. Cardiac Markers, A. H. B Wu. Humana Press, Totowa, NJ 2003; 291–303
   Google Scholar
• Ferreiros E. R., Boissonnet C. P., Pizarro R. Independent prognostic value of C‐reactive protein in unstable angina. Circulation 1999; 100: 1958–63
   PubMed Web of Science ®Google Scholar
• Biasucci L. M., D’onofrio G., Liuzzo G., Zini G., Monaco C., Caligiuri G., Tommasi M., Rebuzzi A. G., Maseri A. Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but it sreduction is not related to ischemia. J Am Coll Cardiol 1996; 27: 611–6
   PubMed Web of Science ®Google Scholar
• Baldus S., Heeschen C., Meinertz T., Zeiher A. M., Eiserich J. P., Munzel T. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440–5
   PubMed Web of Science ®Google Scholar
• Brennan M. L., Penn M. S., Van lente F., Nambi V., Shishehbor M. H., Aviles R. J., Goormastic M. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: 1595–604
   PubMed Web of Science ®Google Scholar
• Bayes‐genis A., Conover C. A., Overgaard M. T., Bailey K. R., Christiansen M., Holmes D. R., Virmani R., Oxvig C., Schwartz R. S. Pregnancy‐associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001; 345: 1022–9
   PubMed Web of Science ®Google Scholar
• Cosin‐sales J., Christiansen M., Kaminski P., Oxvig C., Overgaard M. T., Cole D., Holt D. W., Kaski J. C. Pregnancy‐associated plasma protein A and its endogenous inhibor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris. Circulation 2004; 109: 1724–8
   PubMed Web of Science ®Google Scholar
• Lund J., Qin Q. P., Ilva T., Pettersson K., Voipio‐pulkki L. M., Porela P., Pulkki K. Circulating pregnancy‐associated plasma protein A predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 2003; 108: 1924–6
   PubMed Web of Science ®Google Scholar
• Heeschen C., Dimmeler S., Fichtlscherer S., Hamm C. W., Berger J., Simoons M. L., Zeiher A. M. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 2004; 291: 435–441
   PubMed Web of Science ®Google Scholar
• Massberg S., Schulz C., Gawaz M. Role of platelets in the pathophysiology of acute coronary syndrome. Sem Vasc Med 2003; 3: 147–61
   PubMedGoogle Scholar
• Andre P. P‐selectin in haemostasis. Brit J Haematol 2004; 126: 298–306
   PubMed Web of Science ®Google Scholar
• Prasad K. S. S., Andre P., Yan Y., Phillips D. R. The platelet CD40LGP IIb‐IIIa axis in atherothrombotic disease. Curr Opin Hematol 2003; 10: 356–61
   PubMed Web of Science ®Google Scholar
• Hollander J. E., Muttreja M. R., Dalesandro M. R., Shofer F. S. Risk stratification of emergency department patients with acute coronary syndromes using P‐selectin. J Am Coll Cardiol 1999; 34: 95–105
   PubMedGoogle Scholar
• Heeschen C., Dimmeler S., Hamm C. W., Van den brand M. J., Boersma E., Zeiher A. M., Simoons M. L. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104–11
   PubMed Web of Science ®Google Scholar
• Ahnadi C. E., Chapman S., Lepine M., Okrongly D., Pujol‐moix N., Hernandez A., Boughrassa F., Grant A. M. Assessment of platelet activation in several different anticoagulants by the ADVIA 120 Hematology System, fluorescence flow cytometry, and electron microscopy. Thromb Haemost 2003; 90: 940–8
   PubMed Web of Science ®Google Scholar
• Ahnadi CE. Unpublished observations, 2004.
   Google Scholar
• Shaikh N. A., Downar E. Time course of changes in porcine myocardial phospholipid levels during ischemia. A reassessment of the lysolipid hypothesis. Circ Res 1981; 49: 316–25
   PubMed Web of Science ®Google Scholar
• Apple F. S., Wu A. H. B., Mair J., Ravkilde J., Panteghini M., Tate J., Pagani F., Christenson R. H., Mockel M., Danne O., Jaffe A. S. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005; 51: 486–91
   PubMed Web of Science ®Google Scholar
• Danne O., Mockel M., Leuders C., Mugge C., Zschunke G. A., Lufft H., Muller C., Frei U. Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol 2003; 91: 1060–7
   PubMed Web of Science ®Google Scholar
• Baror D., Lau E., Winkler J. A novel assay for the cobalt‐albumin binding and its potential as a marker for myocardial ischemia: a preliminary report. J Emerg Med 2000; 19: 311–5
   PubMedGoogle Scholar
• Baror D., Winkler J., Vanbenthuysen K., Harris L., Lau E., Hetzel F. Reduced cobalt binding of human albumin with transient myocardial ischemia following elective percutaneous transluminal coronary angioplasty compared to CK‐MB, myoglobin and troponin I. Am Heart J 2001; 141: 985–91
   PubMedGoogle Scholar
• Peacock F. A meta analysis of ischemia modified albumin as a prediction tool to rule out acute coronary syndromes in the emergency department., , et al. In preparation. 2005
   Google Scholar
• Kleinfeld A. M., Prothro D., Brown D., Davis R. C., Richierie G. V., Demaria A. Increases in serum unbound free fatty acid concentrations following coronary angioplasty. Am J Cardiol 1996; 78: 1350–54
   PubMedGoogle Scholar
• Tateishi J., Masutani M., Ohyanagi M., Iwasaki T. Transient increase in plasma brain (B‐type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol 2000; 23: 776–80
   PubMedGoogle Scholar
• Sabatine M. S., Morrow D. A., De lemos J. A., Omland T., Desai M. Y., Tanasijevic M., Hall C., Mccabe C. H., Braunwald E. Acute changes in circulating natriuretic peptide levels in relation to myocardial inschemia. J AM Coll Cardiol 2004; 44: 1988–95
   PubMed Web of Science ®Google Scholar
• Weber M., Dill T., Arnold R., Rau M., Ekinci O., Muller K. D., Berkovitsch A., Mitrovic V., Hamm C. N‐terminal B‐type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. Am Heart J 2004; 148: 612–20
   PubMed Web of Science ®Google Scholar
• De lemos J. A., Morrow D. A., Bentley J. H., Omland T., Sabatine M. S., Mccabe C. H., Hall C., Cannon C. P., Braunwald E. The prognostic value of B‐type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014–21
   PubMed Web of Science ®Google Scholar